Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity

1. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. EJSO 2008; 34: 232-40.10.1016/j.ejso.2007.05.016Search in Google Scholar

2. Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G. Radiosensitizing effect of electrochemotherapy in a fractionated radiation regimen in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model. Radiat Res 2009; 172: 677-85.10.1667/RR1873.1Search in Google Scholar

3. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011; 10: 475-85.10.7785/tcrt.2012.500224Search in Google Scholar

4. Heller R, Gilbert R, Jaroszeski MJ. Clinical trials for solid tumors using electrochemotherapy. Methods Mol Med 2000; 37: 137-56.10.1385/1-59259-080-2:137Search in Google Scholar

5. Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, et al. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. Biomed Eng Online 9: 10.10.1186/1475-925X-9-10Search in Google Scholar

6. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-7.Search in Google Scholar

7. Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 2008; 423: 319-25.10.1007/978-1-59745-194-9_24Search in Google Scholar

8. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 2000; 10: 577-83.10.1097/00008390-200012000-00010Search in Google Scholar

9. Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNFalpha on SA-1 tumors in mice. Cancer Lett 1997; 116: 85-92.10.1016/S0304-3835(97)00170-5Search in Google Scholar

10. Torrero M, Li S. Treatment of SCCVII tumors with systemic chemotherapy and Interleukin-12 gene therapy combination. Methods Mol Biol 2008; 423: 339-49.10.1007/978-1-59745-194-9_2618370212Search in Google Scholar

11. Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 2006; 12: 257-63.10.1158/1078-0432.CCR-05-151416397050Search in Google Scholar

12. Mir LM, Roth C, Orlowski S, Quintin-Colonna F, Fradelizi D, Belehradek J, Jr., et al. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother Emphasis Tumor Immunol 1995; 17: 30-8.10.1097/00002371-199501000-000047537154Search in Google Scholar

13. Kishida T, Asada H, Itokawa Y, Yasutomi K, Shin-Ya M, Gojo S, et al. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 2003; 8: 738-45.10.1016/j.ymthe.2003.08.00214599806Search in Google Scholar

14. Orlowski S, An D, Belehradek J, Jr., Mir LM. Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor. Anticancer Drugs 1998; 9: 551-6.10.1097/00001813-199807000-000069877244Search in Google Scholar

15. Ramirez LH, Orlowski S, An D, Bindoula G, Dzodic R, Ardouin P, et al. Electrochemotherapy on liver tumours in rabbits. Br J Cancer 1998; 77: 2104-11.10.1038/bjc.1998.35421503839649121Search in Google Scholar

16. Andersen MH, Gehl J, Reker S, Geertsen P, Becker JC, thor Stratem P. Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil? J Clin Oncol 2005; 23: 5265-7.Search in Google Scholar

17. Mir LM, Orlowski S, Poddevin B, Belehradek J, Jr. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur Cytokine Netw 1992; 3: 331-4.Search in Google Scholar

18. Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003; 13: 449-59.10.1016/j.semcancer.2003.09.00915001164Search in Google Scholar

19. Cemazar M, Sersa G, Pavlin D, Tozon N. Intramuscular IL-12 Electrogene Therapy for Treatment of Spontaneous Canine Tumors. In: You Y, editor. Targets in Gene Therapy. InTech; 2011. p. 299 - 320.10.5772/20734Search in Google Scholar

20. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10: 300-11.10.2174/15665231079182342520560875Search in Google Scholar

21. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90: 2541-8.Search in Google Scholar

22. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12: 671-84.10.1089/10430340130005738811426466Search in Google Scholar

23. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des 2003; 9: 1981-91.10.2174/138161203345426112871184Search in Google Scholar

24. Prijic S, Prosen L, Cemazar M, Scancar J, Romih R, Lavrencak J, et al. Surface modified magnetic nanoparticles for immuno-gene therapy of murine mammary adenocarcinoma. Biomaterials 2012; 33: 4379-91.10.1016/j.biomaterials.2012.02.06122429983Search in Google Scholar

25. Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573-81.10.2174/156652305774964712Search in Google Scholar

26. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903.10.1200/JCO.2007.15.6794Search in Google Scholar

27. Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10: 312-7.10.2174/156652310791823489Search in Google Scholar

28. Teissie J, Escoffre JM, Paganin A, Chabot S, Bellard E, Wasungu L, et al. Drug delivery by electropulsation: Recent developments in oncology. Int J Pharm 2012; 423: 3-6.10.1016/j.ijpharm.2011.09.038Search in Google Scholar

29. Pavlin D, Cemazar M, Coer A, Sersa G, Pogacnik A, Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 2011; 45: 31-9.10.2478/v10019-010-0041-9Search in Google Scholar

30. Markelc B, Bellard E, Sersa G, Pelofy S, Teissie J, Coer A, et al. In vivo molecular imaging and histological analysis of changes induced by electric pulses used for plasmid DNA electrotransfer to the skin: A study in a dorsal window chamber in mice. J Membr Biol 2012; 245: 545-54.10.1007/s00232-012-9435-5Search in Google Scholar

31. Rebersek M, Cufer T, Cemazar M, Kranjc S, Sersa G. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs 2004; 15: 593-7.10.1097/01.cad.0000132234.30674.dfSearch in Google Scholar

32. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998; 34: 1213-8.10.1016/S0959-8049(98)00025-2Search in Google Scholar

33. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 2000; 10: 381-5.10.1097/00008390-200008000-0001010985673Search in Google Scholar

34. Tamzali Y, Borde L, Rols MP, Golzio M, Lyazrhi F, Teissie J. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases. Equine Vet J 2012; 44: 214-20.10.1111/j.2042-3306.2011.00425.x21793876Search in Google Scholar

35. Spugnini EP, Vincenzi B, Citro G, Dotsinsky I, Mudrov T, Baldi A. Evaluation of Cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs. J Vet Intern Med 2011; 25: 407-11.10.1111/j.1939-1676.2011.0678.x21382075Search in Google Scholar

36. Tozon N, Sersa G, Cemazar M. Electrochemotherapy: potentiation of local antitumour effectiveness of cisplatin in dogs and cats. Anticancer Res 2001; 21: 2483-8.Search in Google Scholar

37. Cemazar M, Pavlin D, Sersa G, Tozon N. Electrogene therapy in veterinary oncology. In: Proceedings of the Fundamental & Applied Bioelectrics, 23-27th 2012 Norfolk, USA: an international scientific workshop. Norfolk: Old Dominion University, 2012, 94-9.Search in Google Scholar

38. Nanni P, de Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983; 1: 373-80.10.1007/BF001211996546207Search in Google Scholar

39. North RJ, Neubauer RH, Huang JJ, Newton RC, Loveless SE. Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med 1988; 168: 2031-43.10.1084/jem.168.6.203121891483143799Search in Google Scholar

40. Rakhmilevich AL, Janssen K, Hao ZL, Sondel PM, Yang NS. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther 2000; 7: 826-38.10.1038/sj.cgt.770017610880012Search in Google Scholar

41. Oshikawa K, Shi FS, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1 beta converting enzyme cDNA. Proc Natl Acad Sci U S A 1999; 96: 13351-6.10.1073/pnas.96.23.133512395110557324Search in Google Scholar

42. Di Carlo E, Cappello P, Sorrentino C, D’Antuono T, Pellicciotta A, Giovarelli M, et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol 2005; 205: 82-91.10.1002/path.167915586367Search in Google Scholar

43. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6.Search in Google Scholar

44. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 2002; 87: 1047-54.10.1038/sj.bjc.6600606236431412434299Search in Google Scholar

45. Marty M, Sersa G, Garbay J, Gehl J, Collins C, Snoj M, et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006; 4: 3-13.10.1016/j.ejcsup.2006.08.002Search in Google Scholar

46. Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs 1998; 9: 525-30.10.1097/00001813-199807000-000029877240Search in Google Scholar

47. Tevz G, Pavlin D, Kamensek U, Kranjc S, Mesojednik S, Coer A, et al. Gene electrotransfer into murine skeletal muscle: a systematic analysis of parameters for long-term gene expression. Technol Cancer Res Treat 2008; 7: 91-101.10.1177/15330346080070020118345697Search in Google Scholar

48. Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krzan M, et al. Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009; 11: 1125-37.10.1002/jgm.1403Search in Google Scholar

49. Corbett TH, Valeriote FA. Rodent models in experimental chemotherapy. In: Kallman RF, editor. Rodent Tumour Models in Experimental Cancer Therapy. New York: Pergamon Press; 1987. p. 233-47.Search in Google Scholar

50. Sersa G, Cufer T, Paulin SM, Cemazar M, Snoj M. Electrochemotherapy of chest wall breast cancer recurrence. Cancer Treat Rev 2012; 38: 379-86.10.1016/j.ctrv.2011.07.006Search in Google Scholar

51. Cemazar M, Miklavcic D, Sersa G. Intrinsic sensitivity of tumor cells to bleomycin as an indicator of tumor response to electrochemotherapy. Jpn J Cancer Res 1998; 89: 328-33.10.1111/j.1349-7006.1998.tb00566.xSearch in Google Scholar

52. Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450-5.Search in Google Scholar

53. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2012, http://dx.doi.org/10.1016/j.ejso.2012.08.016;Search in Google Scholar

54. Sersa G, Kotnik V, Cemazar M, Miklavcic D, Kotnik A. Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice--natural resistance and immune responsiveness. Anticancer Drugs 1996; 7: 785-91.10.1097/00001813-199609000-00011Search in Google Scholar

55. Sersa G, Cemazar M, Miklavcic D, Mir LM. Electrochemotherapy: variable anti-tumor effect on different tumor models. Biolectroch Bioener 1994; 36: 83-7.Search in Google Scholar

56. Sersa G, Miklavcic D, Cemazar M, Belehradek J, Jr., Jarm T, Mir LM. Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient mice. Biolectroch Bioener 1997; 43: 279-83.10.1016/S0302-4598(96)05194-XSearch in Google Scholar

57. Cemazar M, Miklavcic D, Mir LM, Belehradek J, Jr., Bonnay M, Fourcault D, et al. Electrochemotherapy of tumours resistant to cisplatin: a study in a murine tumour model. Eur J Cancer 2001; 37: 1166-72.10.1016/S0959-8049(01)00091-0Search in Google Scholar

58. Orlowski S, Belehradek J, Jr., Paoletti C, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37: 4727-33.10.1016/0006-2952(88)90344-9Search in Google Scholar

59. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-98.10.1038/sj.bjc.6604168236146418182988Search in Google Scholar

60. Corovic S, Mir LM, Miklavcic D. In vivo muscle electroporation threshold determination: realistic numerical models and in vivo experiments. J Membr Biol 2012; 245: 509-20..10.1007/s00232-012-9432-822622286Search in Google Scholar

61. Quaglino P, Osella-Abate S, Marenco F, Nardo T, Gado C, Novelli M, et al. FoxP3 expression on melanoma cells is related to early visceral spreading in melanoma patients treated by electrochemotherapy. Pigm Cell Melanoma R 2011; 24: 734-6.10.1111/j.1755-148X.2011.00879.x21696572Search in Google Scholar

62. Mir LM, Roth C, Orlowski S, Belehradek J, Jr., Fradelizi D, Paoletti C, et al. [Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2]. C R Acad Sci III 1992; 314: 539-44.Search in Google Scholar